Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the stocks on Jim Cramer’s radar. Cramer discussed the company’s latest acquisition announcement and commented: “We got some sizable deals ...

Zimmer Biomet has entered into a definitive agreement to acquire Monogram Technologies, an orthopedic robotics company. Zimmer will pay $4.04 per share in cash to acquire all outstanding shares of ...

Zimmer Biomet Holdings Inc (NYSE:ZBH), a leading player in the medical devices industry, has been making strategic moves to strengthen its market position and expand its product portfolio. With an ...

Zimmer Biomet operates in the U.S. Medical Supplies & Devices sector, which currently holds a positive industry outlook. The company has been actively pursuing growth through strategic acquisitions.

Zimmer Biomet is expected to announce its second-quarter results in the upcoming month, and analysts expect a low-single-digit drop in earnings.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported net sales of $1.909 million in Q1, reflecting a 1.1% increase on a reported basis and a 2.3% rise when excluding the effects of foreign currency. While ...

Zimmer Biomet and Monogram undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this ...

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers.

Zimmer Biomet CEO Ivan Tornos joined the Orthopaedic Research and Education Foundation board, according to a May 29 news release.

The Zimmer Biomet Oxford Cementless Partial Knee System received FDA approval in November, although the implant has been used in more than 300,000 procedures outside the U.S.

Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and ...